drugset
drugset / Trial / NCT02976129

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

NCT02976129 ↗

Phase 2 Completed 125 enrolled VHsquared Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease (CD).

Timeline

Start
2016-12
Primary completion
2019-03-08
Completion
2019-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject V565 Protein / enzyme biologic — Oral

Indications

Crohn disease